Announcements Trials
Browse Landscape

Status

Completed 3Withdrawn 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 41Observational 4

Sponsor

Cancer Type

Genitourinary 4Lymphoid 2Tumor-Agnostic 1

Conditions

Carcinoma, Renal Cell 4Lymphoma, Mantle-Cell 1

Interventions

Surveys and Questionnaires 52Blood Specimen Collection 47enzalutamide 29radium Ra 223 dichloride 22Biopsy 20darolutamide 19Radiotherapy 19Docetaxel 19apalutamide 18Sunitinib 18Magnetic Resonance Spectroscopy 18Sorafenib 17Abiraterone Acetate 17Watchful Waiting 16Interviews as Topic 15Gene Expression Profiling 15Amplified Fragment Length Polymorphism Analysis 15Observation 13Leuprolide 13Immunohistochemistry 13Androgen Antagonists 13acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 12Magnetic Resonance Imaging 12avelumab 11Specimen Handling 11abiraterone 9Polymerase Chain Reaction 9Flow Cytometry 9Radiosurgery 8Microarray Analysis 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × temsirolimus × Genitourinary × Clear all
NCT02184416 2026-02-27

ADONIS

Pfizer

Completed
554 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT01210482 2024-09-25

Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Pfizer

Completed
1,050 enrolled 9 charts
Genitourinary

Carcinoma, Renal Cell

NCT01367457 2016-04-27

INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus

Pfizer

Completed
243 enrolled 12 charts
GenitourinaryLymphoid

Carcinoma, Renal Cell, Lymphoma, Mantle-Cell

NCT01781442 2013-05-01

A Post Marketing Surveillance As Required By Philippine Food And Drug Administration

Pfizer

Withdrawn
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡